Comparison of Post-transplant Cyclophosphamide Containing Immunosuppressive Regimen with Standard Immunosuppressive Regimen in Allogeneic Stem Cell Transplantation from Matched Sibling Donor
Aim:Allogeneic stem cell transplantation (ASCT) is the only treatment that can cure most of malignant hematological diseases with the risk of some serious complications such as graft-versus-host disease (GVHD). GVHD can be got under control with post-transplant cyclophosphamide even in patients with...
Main Authors: | Osman KARA, Tayfun ELİBOL |
---|---|
Format: | Article |
Language: | English |
Published: |
Galenos Yayincilik
2021-12-01
|
Series: | Namık Kemal Tıp Dergisi |
Subjects: | |
Online Access: |
http://namikkemalmedj.com/archives/archive-detail/article-preview/comparison-of-post-transplant-cyclophosphamide-con/49752
|
Similar Items
-
Post-Transplant Cyclophosphamide and Tacrolimus—Mycophenolate Mofetil Combination Governs GVHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors
by: Fabrizio Carnevale-Schianca, et al.
Published: (2021-03-01) -
Post-transplant cyclophosphamide versus anti-thymocyte globulin in allogeneic hematopoietic stem cell transplantation from unrelated donors: A systematic review and meta-analysis
by: Lu Tang, et al.
Published: (2023-02-01) -
Cyclophosphamide-Induced Tolerance in Allogeneic Transplantation: From Basic Studies to Clinical Application
by: Koji Kato, et al.
Published: (2020-01-01) -
Haploidentical Hematopoietic Stem Cell Transplantation Followed by ‘Post-Cyclophosphamide’: The Future of Allogeneic Stem Cell Transplant
by: Samuel Cytryn, et al.
Published: (2020-04-01) -
Graft‐versus‐leukaemia immunity is retained following treatment with post‐transplant cyclophosphamide alone or combined with tocilizumab in humanised mice
by: Chloe Sligar, et al.
Published: (2024-01-01)